The invention relates to a nutritional composition comprising human milk oligosaccharide (HMO) having an effect on in a mammal to improve, enhance, promote or modulate a GABAergic function in the CNS, preferably in a human infant or a young children between birth and 7 years. The composition can be an infant formula. The HMO may be 2FL, diFL and/or LNT and or LNnT or combinations thereof.

The invention discloses a composition comprising oligosaccharide, for use in the prevention and/or treatment of skin conditions and/or skin diseases by increasing SCFA, in particular colonic propionate and butyrate. Said skin disease is in particular atopic dermatitis.

The invention concerns composition comprising 2′-fucosyllactose for use in the treatment of virus induced diarrhea.

The present invention discloses palatable oral formulations for hydrating, supporting gut activity, micronutrient supplementation and providing oral carriers for vaccines, antibiotics and food supplements, of inter alia, companion or pet animals.

The present invention discloses palatable oral formulations for hydrating, supporting gut activity, micronutrient supplementation and providing oral carriers for vaccines, antibiotics and food supplements, of inter alia, companion or pet animals.

A method for producing and purifying human milk oligosaccharides (HMOs) is provided. The method includes fermentation of a genetically modified microbial organism, preferably a genetically modified yeast strain, and downstream processing of the fermentation product using one or more of an enzymatic treatment, filtration, and a simulated moving bed (SMB) chromatography step. Use of the resulting HMO in food or feed applications, preferably in infant food and/or formula is also provided.

A method for producing and purifying human milk oligosaccharides (HMOs) is provided. The method includes fermentation of a genetically modified microbial organism, preferably a genetically modified yeast strain, and downstream processing of the fermentation product using one or more of an enzymatic treatment, filtration, and a simulated moving bed (SMB) chromatography step. Use of the resulting HMO in food or feed applications, preferably in infant food and/or formula is also provided.

The invention discloses a composition comprising LNT and at least another human milk oligosaccharide or precursor thereof, for use in preventing and/or treating necrotizing enterocolitis in infants and young children.

The invention discloses a composition comprising LNT and at least another human milk oligosaccharide or precursor thereof, for use in preventing and/or treating necrotizing enterocolitis in infants and young children.

The present invention relates to a non-digestible prebiotic oligosaccharide modified so as to incorporate one or more monosaccharide units thereon and have a higher sweetness value than the unmodified oligosaccharide. Uses and methods of producing the non-digestible prebiotic oligosaccharides are also described.